

Financial Results for the First Quarter of the Year Ending March 31, 2020

August 6, 2019

NIKON CORPORATION



FY2020/3 Q1 Actual	 Revenue and Operating profit dropped ¥24.0B and ¥9.7B, respectively, YoY due to sales volume reduction in entry/mid DSLR cameras and FPD lithography systems, etc. Q1 OP resulted in ¥9.3B, 51% down YoY, yet proceeding accordingly to the full-year forecast. Buy-back of 6,667,200 shares was conducted at approx. ¥10.0B from May 10 to June 20, 2019, which accounts for approx. 1.7% of the outstanding shares.
FY2020/3	 Revenue: 1H ¥290B, full-year ¥670B (unchanged from the previous forecast) Operating profit: 1H ¥15B, full-year ¥52B (unchanged from the previous forecast) Profit attributable to owners of the parent:
Forecast	1H ¥13B, full-year ¥42B (unchanged from the previous forecast) ROE : 7% Annual dividend: ¥60 (Interim: ¥30, expected payout ratio: 56.1%)

1st Quarter of the Year ending March 31, 2020: Financial Highlights



Billions of yen	FY2019/3 Q1 (A)	FY2020/3 Q1 (B)	Change (B)- (A)
Revenue	166.9	142.9	-24.0
Operating Profit % vs Revenue	19.0 11.4%	9.3 6.5%	-9.7
Profit before income taxes % vs Revenue	21.9 13.1%	10.7 7.5%	-11.2
Profit attributable to owners of the parent % vs Revenue	16.3 9.8%	8.2 5.7%	-8.1
FCF	27.6	-0.7	-28.3
Exchange Rate: US \$ EURO	¥ 109 ¥ 130	¥110 ¥124	Impact on Revenue -1.9 Impact on Operating Profit -0.9

FCF decreased YoY due to reduction of advances received and the changes of payment terms for the domestic partner companies, etc.

1st Quarter of the Year ending March 31, 2020: Financial Highlights by Segment



Billions of yen		FY2019/3 Q1 (A)	FY2020/3 Q1 (B)	Change (B)- (A)
Imaging	Revenue	79.1	67.3	-15%
Products Business	Operating Profit	12.4	3.5	-¥8.9B
Precision	Revenue	59.0	50.9	-14%
Equipment Business	Operating Profit	14.1	10.1	-¥4.0B
Healthcare	Revenue	13.3	12.9	-3%
Business	Operating Profit	-2.1	-1.9	¥ 0.2B
Industrial	Revenue	15.4	11.7	-24%
Metrology and Others	Operating Profit	1.1	0.4	-¥0.7B
Corporate Profit/ Loss non-	Revenue	-	-	-
attributable to any reportable segments	Operating Profit	-6.5	-2.9	+ ¥ 3.6B
Compalidated	Revenue	166.9	142.9	-14%
Consolidated	Operating Profit	19.0	9.3	-¥9.7B

Corporate profit/ loss non-attributable to any reportable segments includes the gain from sales of unused land of ¥3.8B.

1st Quarter of the Year ending March 31, 2020: Imaging Products Business



Billions of yen	FY2019/3 Q1 (A)	FY2020/3 Q1 (B)	Change (B)- (A)
Revenue	79.1	67.3	-11.8
Operating Profit % vs Revenue	12.4 15.7%	3.5 5.2%	-8.9
Digital Camera- Interchangeable Lens type (Units sold: 1,000)	570	450	-120
Interchangeable Lens (Units sold: 1,000)	890	740	-150
Compact DSC (Units sold: 1,000)	430	270	-160

Q1 YoY Change:

- The unit sales of the high-end full-frame camera increased mainly in Europe and US thanks to a growth in sales of ML camera. However, revenue dropped, impacted largely by the reduced sales of entry/mid DSLR cameras in Asia including China.
- In addition to the sales impact above, the initial development cost for new ML camera lenses suppressed the profit.

1st Quarter of the Year ending March 31, 2020: Precision Equipment Business



Billions of yen	FY2019/3 Q1 (A)	FY2020/3 Q1 (B)	Change (B)- (A)
Revenue	59.0	50.9	-8.1
Operating Profit % vs Revenue	14.1 23.9%	10.1 19.8%	-4.0
FPD Lithography Systems (units)	19	9	-10
Semiconductor Lithography Systems New/Refurbished (units)	3/4	6/1	+3/-3

Q1 YoY Change:

- For FPD lithography business, revenue and profit decreased due to a substantial reduction of G8 sales as Chinese manufacturers' investment for TV panel had shifted from G8 to G10.5.
- For Semiconductor lithography business, both revenue and profit increased thanks to a growth in sales of new systems including ArF immersion systems.

1st Quarter of the Year ending March 31, 2020: Healthcare Business



Billions of yen	FY2019/3 Q1 (A)	FY2020/3 Q1 (B)	Change (B)- (A)
Revenue	13.3	12.9	-0.4
Operating Profit % vs Revenue	-2.1 -15.8%	-1.9 -14.7%	+0.2

Q1 YoY change:

- Although sales of retinal diagnostic imaging system increased, overall revenue resulted in a slight decrease as sales of biological microscope declined in regions besides from US.
- Deficit was suppressed by improving the biological microscope cost and focusing investment themes on the long-term growth areas, etc.

1st Quarter of the Year ending March 31, 2020: Industrial Metrology and Others



Billions of yen	FY2019/3 Q1 (A)	FY2020/3 Q1 (B)	Change (B)- (A)
Revenue	15.4	11.7	-3.7
Operating Profit % vs Revenue	1.1 7.1%	0.4 3.4%	-0.7

Q1 YoY change:

• Revenue was adversely affected by delayed investment of customers in both Industrial Metrology and other businesses. The impact of profit reduction was partially compensated by curbing expenses.

Forecast for the Year ending March 31, 2020: Financial Highlights



Billions of yen	FY2019/3 Actual (A)	Previous Forecast (May 9) (B)	New Forecast (Aug. 6) (C)	Change (C)-(A)	Change (C)-(B)	
Revenue	708.6	670.0	670.0	-38.6	±0.0	
Operating Profit	82.6	52.0	52.0	-30.6	±0.0	
% vs Revenue	11.7%	7.8%	7.8%			
Profit before income taxes	87.9	55.0	55.0	-32.9	±0.0	
% vs Revenue	12.4%	8.2%	8.2%	5215	_010	
Profit attributable to owners of the parent	66.5	42.0	42.0	-24.5	±0.0	
% vs Revenue	9.4%	6.3%	6.3%	-24.3	±0.0	
EPS	¥ 167.86	¥ 105.99	¥ 106.89	-¥60.97	+¥0.90	
Annual Dividends	¥ 60	¥ 60	¥60	±0	±0.0	
FCF	43.5	40.0	40.0	-3.5	±0.0	
Exchange Rate:				Impact or	Revenue	
US \$	¥ 111	¥ 105	¥106	approx15.4	approx.+2.4	
	V 1 7 0	V 12E	V 125	Impact on Op	erating Profit	
EURO	¥128	¥ 125	¥125	approx3.3	approx0.1	

Note: EPS (Basic Earnings per Share) = Profit attributable to owners of the parent / Average number of shares during the term

Only the new forecast is calculated by approx. 0.393B shares, an average over the number of shares at the end of FY2019/3, approx. 0.396B, and the expected number of shares at the end of FY2020/3.

Forecast for the Year ending March 31, 2020: Financial Highlights by Segment




Billions of yen	_	FY2019/3 Actual (A)	Previous Forecast (May 9) (B)	New Forecast (Aug. 6) (C)	Change (C)-(A)	Change (C)-(B)
Imaging	Revenue	296.1	260.0	260.0	-12.2%	±0.0%
Products Business	Operating Profit	22.0 (22.6)	12.0	12.0	-¥10.0B	±¥0.0B
Precision	Revenue	274.5	270.0	270.0	-1.6%	±0.0%
Equipment Business	Operating Profit	81.7 (81.7)	56.0	56.0	-¥25.7B	±¥0.0B
	Revenue	65.4	65.0	65.0	-0.6%	±0.0%
Healthcare Business	Operating Profit	-1.9 (-1.9)	-1.0	-1.0	+¥0.9B	±¥0.0B
Industrial	Revenue	72.5	75.0	75.0	+3.4%	±0.0%
Metrology and Others	Operating Profit	6.9 (7.5)	6.0	6.0	-¥0.9B	±¥0.0B
Corporate	Revenue	_	_	-	-	_
Profit/Loss non- attributable to any reportable segments	Operating Profit	-26.1 (-25.6)	-21.0	-21.0	+¥5.1B	±¥0.0B
	Revenue	708.6	670.0	670.0	-5.4%	±0.0%
Consolidated	Operating Profit	82.6 (84.4)	52.0	52.0	- ¥ 30.6B	±¥0.0B

Note: Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

Forecast for the Year ending March 31, 2020: Imaging Products Business





• Revenue: Forecast unchanged, ¥36.1B down YoY


- Camera market continues to shrink. Sales volume reduction is expected in each category.
- Although efforts will be continuously made to expand the sales of ML cameras and Z mount lenses, declining revenue of entry/mid DSLR and compact DSC is expected to suppress the overall revenue.

• OP: Forecast unchanged, ¥10.0B down YoY

- Investment for ML lineup expansion increases compared to the previous year.
- Thorough cost-effective measures are implemented to reduce SG&A, etc. to recover a part of profit reduction.

Forecast for the Year ending March 31, 2020: Precision Equipment Business





• Revenue: Forecast unchanged, ¥4.5B down YoY


- FPD: Sales of high-priced G10.5 are expected to grow, yet revenue decreases substantially due to G6/G8 unit sales reduction.
- Semiconductor: Main customer's CAPEX continues to be steady. Revenue is lifted by new system sales increase.

• OP: Forecast unchanged, ¥25.7B down YoY

- OP for FY2019/3 is approx. ¥66.7B excluding the temporary profit from litigation settlement.
- Profit reduction of FPD is partially recovered by Semiconductor profit hike.

Forecast for the Year ending March 31, 2020: Healthcare Business





• Revenue: Forecast unchanged, ¥0.4B down YoY


- Both biological microscopes and retinal diagnostic imaging systems are performing steadily, yet the flat revenue is expected due to the negative forex impact.

• OP: Forecast unchanged, ¥0.9B up YoY

- More focused investment is conducted in the regenerative medicine and ophthalmological diagnosis fields to halve the deficit, aiming to generate profit in the next FY.

Forecast for the Year ending March 31, 2020: Industrial Metrology Business and Others





• Revenue: Forecast unchanged, ¥2.5B up YoY

 Industrial metrology: Revenue growth is expected by expanding the market share of X-ray inspection systems and non-contact 3D metrology systems.

• OP: Forecast unchanged, ¥0.9B down YoY

- Industrial metrology: Profitability is steadily improving through restructuring.
- Profit in the whole segment decreases as investment continues for future growth in precision component & modules business, etc.



Forward-looking statements for earnings and other performance data contained herein are based on information currently available to the Company, and all potential risks and uncertainties are taken into account. The Company asks that investors understand that changes in conditions may cause actual performance to significantly differ from these projections.





Reference Data

Forecast for the Year ending March 31, 2020: Financial Highlights (Half Year/Full Year)



	FY2017/3	FY2018/3		FY2019/3		FY	2020/3 Foreca	ist
Billions of yen	Full Year	Full Year	H1	H2	Full Year	H1	H2	Full Year
Revenue	749.2	717.0	335.7	372.9	708.6	290.0	380.0	670.0
Operating Profit % vs Revenue	0.7 0.1%	56.2 7.8%	30.6 9.1%	52.0 13.9%	82.6 11.7%	15.0 5.2%	37.0 9.7%	52.0 7.8%
Profit before income taxes	3.0	56.2	33.8	54.1	87.9	17.0	38.0	55.0
% vs Revenue	0.4%	7.8%	10.1%	14.5%	12.4%	5.9%	10.0%	8.2%
Profit attributable to owners of the parent	3.9	34.7	22.8	43.7	66.5	13.0	29.0	42.0
% vs Revenue	0.5%	4.8%	6.8%	11.7%	9.4%	4.5%	7.6%	6.3%
ROE	0.7%	6.3%		11.2%			7%	
FCF	56.6	90.2	43.5				40.0	
Exchange Rate: US \$ EURO	¥ 108 ¥ 119	¥ 111 ¥ 130	¥ 110 ¥ 130	¥ 112 ¥ 127	¥ 111 ¥ 128		¥106 ¥125	

Note: From FY2019/3, a part of sales promotion expenses is deducted from revenue, which had been booked as SG&A previously. FY2019/3 Revenue is an amount after deducting ¥8.3B.

Forecast for the Year ending March 31, 2020: Financial Highlights by Segment (Half Year/Full Year)



		FY2017/3	Y2017/3 FY2018/3 FY2019/3		FY2019/3		Fored	cast for FY20	20/3
Billions of yen		Full Year	Full Year	H1	H2	Full Year	H1	H2	Full Year
Imaging	Revenue	383.0	360.7	150.9	145.2	296.1	120.0	140.0	260.0
Products Business	Operating Profit	17.1 (28.1)	30.2 (36.0)	13.2 (13.6)	8.8 (9.0)	22.0 (22.6)	3.0	9.0	12.0
Precision	Revenue	248.0	226.3	121.6	152.9	274.5	110.0	160.0	270.0
Equipment Business	Operating Profit	13.4 (48.1)	53.3 (53.3)	29.8 (29.8)	51.9 (51.9)	81.7 (81.7)	23.0	33.0	56.0
Healthcare	Revenue	55.7	56.8	29.4	36.0	65.4	30.0	35.0	65.0
Business	Operating Profit	-0.6 (-0.1)	-3.2 (-3.2)	-2.3 (-2.3)	0.4 (0.4)	-1.9 (-1.9)	-3.0	2.0	-1.0
Industrial	Revenue	62.4	73.2	33.7	38.8	72.5	30.0	45.0	75.0
Metrology and Others	Operating Profit	3.7 (5.5)	5.0 (7.8)	2.7 (3.5)	4.2 (4.0)	6.9 (7.5)	1.0	5.0	6.0
Corporate	Revenue	—	_	_	_	-	-	_	-
Profit/Loss non- attributable to any reportable segments	Operating Profit	-32.8 (-27.5)	-29.1 (-29.1)	-12.8 (-12.8)	-13.3 (-12.8)	-26.1 (-25.6)	-9.0	-12.0	-21.0
	Revenue	749.2	717.0	335.7	372.9	708.6	290.0	380.0	670.0
Consolidated	Operating Profit	0.7 (54.1)	56.2 (64.9)	30.6 (31.8)	52.0 (52.6)	82.6 (84.4)	15.0	37.0	52.0

Note: From FY2019/3, a part of sales promotion expenses is deducted from revenue, which had been booked as SG&A previously. FY2019/3 Revenue is an amount after deducting ¥8.3B. Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

1st Quarter of the Year ending March 31, 2020: Financial Highlights by Segment




			FY2020/3			
Billions of yen		Q1	Q2	Q3	Q4	Q1
Imaging	Revenue	79.1	71.8	90.5	54.7	67.3
Products	Operating	12.4	0.8	8.6	0.2	3.5
Business	Profit	(12.4)	(1.2)	(8.6)	(0.4)	
Precision	Revenue	59.0	62.6	64.7	88.2	50.9
Equipment	Operating	14.1	15.7	17.4	34.5	10.1
Business	Profit	(14.1)	(15.7)	(17.4)	(34.5)	
Healthcare	Revenue	13.3	16.1	16.3	19.7	12.9
Business	Operating	-2.1	-0.2	-0.2	0.6	-1.9
	Profit	(-2.1)	(-0.2)	(-0.2)	(0.6)	
Industrial	Revenue	15.4	18.3	19.0	19.8	11.7
Metrology and	Operating	1.1	1.6	2.1	2.1	0.4
Others	Profit	(1.1)	(2.4)	(2.1)	(1.9)	
Corporate Profit/Loss non-	Revenue	-	_	_	-	-
attributable to any reportable segments	Operating	-6.5	-6.3	-6.0	-7.3	-2.9
Segments	Profit	(-6.5)	(-6.3)	(-6.0)	(-6.8)	
	Revenue	166.9	168.8	190.5	182.4	142.9
Consolidated	Operating	19.0	11.6	21.9	30.1	9.3
	Profit	(19.0)	(12.8)	(22.0)	(30.6)	

Note: Figures in parentheses are the operating profit excluding the restructuring relevant expenses.

1st Quarter of the Year ending March 31, 2020: **Financial Position Breakdown**





ASSETS

LIABILITIES/ EQUITY

Note: A breakdown of the interest-bearing debt as of the end of June 2019, is bond of ¥29.9B and other borrowings of ¥112.4B. Equity ratio is a ratio of equity attributable to owners of the parent to total assets. Cash and Cash Equivalents excludes time deposits with maturities of three months or more.

Forecast for the Year ending March 31, 2020: Capital Expenditures, Depreciation and Inventory




CAPITAL EXPENDITURES, DEPRECIATION **INVENTORY BREAKDOWN** ¥50B-¥300B-263.9 253.3 248.7 250.0 Industrial 38.8 235.5 40· 38.2 Metrology and 36.8 33.0 36.0 Others 33.9 _{33.4} 34.4 33.6 16.9 33.0 15.7 15.0 Healthcare 32.2 14.5 32.0 31.7 200-15.2 30-27.8 24.9 147.6 Precision 136.6 148.0 141.9 20 131.5 Equipment 100-10 Imaging 64.2 61.2 56.3 55.2 54.0 Products n 17/318/3 19/3 20/316/318/3 18/6 19/3 19/6 20/3 Forecast Forecast

Capital Expenditures 📃 Depreciation


Note: In FY2020/3, "CAPITAL EXPENDITURES" includes the leased asset of approx. ¥3.0B upon the adoption of IFRS16. "DEPRECIATION" includes the amortization of capitalized R&D costs from the FY2018/3 and depreciation of the leased asset of approx. ¥4.0B in FY2020/3, as mentioned above.





Note: The outside and inside circles show the breakdown of FY2020/3 Q1 revenue of ¥142.9B and FY2019/3 1Q revenue of ¥166.9B, respectively.






Note: R&D expenditures from FY2018/3 include capitalization of some development expenditures.


Cash Flow History





Note: FCF (free cash flows) = CF from operating activities + CF from investing activities; Japanese Standard is employed for FY2015/3 and prior, and IFRS is adopted for FY2016/3 and after. FCF + CF from financial activities + Effect of exchange rate changes on cash and cash equivalents = Net increase (decrease) in cash and cash equivalents






Note: Buy-back of shares at approx. ¥10.0B was conducted in FY 2020/3 1Q.


1st Quarter of the Year ending March 31, 2020: Imaging Products Business






Forecast for the Year ending March 31, 2020: Precision Equipment Business






1st Quarter of the Year ending March 31, 2020: Precision Equipment Business





1st Quarter of the Year ending March 31, 2020: Precision Equipment Business







	Exchange Rate	Financial Impact from Fluctuation by 1 yen	
	FY2020/3 Forecast for Q2~Q4	Revenue Q2~Q4	Operating Profit Q2~Q4
US \$	¥ 105	Approx. ¥ 1.9billion	Approx. ¥0.3billion
EURO	¥ 125	Approx. ¥0.5billion	Approx. ¥ 0.2billion

Note: The foreign exchange impact above is made on the assumption that emerging-market currencies move according to the influence of US \$ and EURO.

